| 发明名称 |
METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION |
| 摘要 |
An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient. |
| 申请公布号 |
US2016102366(A1) |
申请公布日期 |
2016.04.14 |
| 申请号 |
US201414895286 |
申请日期 |
2014.06.19 |
| 申请人 |
TAIHO PHARMACEUTICAL CO., LTD. |
发明人 |
ABE Tetsuya;ITAKDANI Hiraku |
| 分类号 |
C12Q1/68;A61K31/4745;A61K31/436;G01N33/574;A61K31/4375;A61K31/5377 |
主分类号 |
C12Q1/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for predicting therapeutic efficacy of a chemotherapy using an antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of an expression level of PHLDA1 and/or PIK3C2B in tumor cells isolated from the cancer patient. |
| 地址 |
Tokyo JP |
